TargetBeta
CD74
CD74 molecule · also CLIP, DHLAG · CD molecules
1 program in company-led studies act on CD74, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 93 running | ALK, NTRK1, NTRK2, NTRK3, PTK2, ROS1, SDC4, SRC | ChEMBL |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 1 program
- Lymphoma, 1 program
- Lymphoma, Follicular, 1 program
- Neoplasm Metastasis, 1 program
- Sarcoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 16, 2027repotrectinib · Bristol-Myers Squibb · phase 3 · NCT06140836
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.